{"title":"自身免疫性非典型帕金森病：原始队列的10年随访","authors":"Sreelakshmi Sunil Kumar, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Anandkumar Anandakuttan, Saraf Udit Umesh, Gopikrishnan Unnikrishnan, Meena Thevarkalam, Annamma Mathai, Uday Kumar Rangaswamy, Abish Sudhakar","doi":"10.1007/s10072-025-07995-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.</p><p><strong>Objective: </strong>To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.</p><p><strong>Design: </strong>Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.</p><p><strong>Measurements: </strong>The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.</p><p><strong>Results: </strong>Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.</p><p><strong>Conclusions: </strong>Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"1883-1890"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autoimmune Atypical Parkinsonism: A 10 year follow up of the original cohort.\",\"authors\":\"Sreelakshmi Sunil Kumar, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Anandkumar Anandakuttan, Saraf Udit Umesh, Gopikrishnan Unnikrishnan, Meena Thevarkalam, Annamma Mathai, Uday Kumar Rangaswamy, Abish Sudhakar\",\"doi\":\"10.1007/s10072-025-07995-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.</p><p><strong>Objective: </strong>To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.</p><p><strong>Design: </strong>Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.</p><p><strong>Measurements: </strong>The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.</p><p><strong>Results: </strong>Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.</p><p><strong>Conclusions: </strong>Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.</p>\",\"PeriodicalId\":19191,\"journal\":{\"name\":\"Neurological Sciences\",\"volume\":\" \",\"pages\":\"1883-1890\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10072-025-07995-1\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10072-025-07995-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Autoimmune Atypical Parkinsonism: A 10 year follow up of the original cohort.
Background: In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.
Objective: To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.
Design: Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.
Measurements: The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.
Results: Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.
Conclusions: Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.
期刊介绍：
Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles, short communications, editorials, reviews and letters to the editor. Original articles present the results of experimental or clinical studies in the neurosciences, while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology, Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews, meeting reports and announcements.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
